We are currently focused on achieving collaborations and distribution agreements with multinational companies, that would allow us to enrich our portfolio with Specialty and Rare Diseases products as also products from the therapeutic areas of Immunology, Haematology and Oncology. Our main interest lies in new and innovative therapeutic approaches with or without orphan drug status, where Phase III clinical trials have been completed and for which FDA and EMA marketing authorization procedures have started or are expected to start.